SCHEMBL1612364

SCHEMBL1612364

CCCCN(C(=O)O)C1CC(S(=O)(=O)c2ccc(C)cc2)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.39
ELOVL6 Q9H5J4 1/20 0.39
ALDH1A1 P00352 3/20 0.38
LMNA P02545 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
ALB P02768 1/20 0.38
CYP2C9 P11712 1/20 0.38
TSHR P16473 1/20 0.38
CNR2 P34972 2/20 0.38
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
RECQL P46063 1/20 0.35
TAS2R14 Q9NYV8 1/20 0.35
KEAP1 Q14145 1/20 0.35
NFE2L2 Q16236 1/20 0.35
ESR1 P03372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4621841 0.71 TSHR (0.47) ALDH1A1LMNATDP1ALBCYP2C9
SCHEMBL989406 0.70 ALDH1A1 (0.51) ELOVL6ALDH1A1CYP2C9TSHRRECQL
SCHEMBL1612684 0.70 L3MBTL1 (0.39) ALDH1A1LMNACNR2
SCHEMBL4165100 0.68 ELOVL6 (0.49) ELOVL6ALDH1A1LMNATDP1TSHR
SCHEMBL3694171 0.67 CNR2 (0.58) MCHR1ALDH1A1LMNATDP1CNR2
SCHEMBL3517002 0.67 CNR2 (0.44) MCHR1ALDH1A1LMNATDP1ALB
SCHEMBL8629867 0.66 KEAP1 (0.57) ALDH1A1TDP1CNR2TAS2R14KEAP1
SCHEMBL1612308 0.66 TRPM8 (0.50) ALDH1A1TDP1TSHR
SCHEMBL6631588 0.65 OPRM1 (0.39) ALDH1A1LMNAATM
SCHEMBL14229013 0.65 CA9 (0.61) MCHR1CNR2PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110086842-A1 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086842-A1 Pyrimidines as PLK inhibitors PLK2, PLK3, TYMP MCHR1 4720/4885ELOVL6 4061/4885ALDH1A1 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.